JPRN-jRCT1071220082
Recruiting
未知
A multicenter, prospective, observational study investigating the efficacy and safety of polatuzumab vedotin plus R-CHP therapy in patients with previously untreated diffuse large B-cell lymphoma - POLASTAR
Kato Koji0 sites500 target enrollmentDecember 23, 2022
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diffuse large B-cell lymphom
- Sponsor
- Kato Koji
- Enrollment
- 500
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients with previously untreated diffuse large B\-cell lymphoma
- •2\. Patients who are scheduled to undergo polatuzumab vedotin (Pola) plus R\-CHP therapy as medical practice based on the latest package insert of Pola
- •3\. Patients who have received a sufficient explanation about the content of this study, have provided voluntary written informed consent from themselves, and are able to comply with the requirements of the study protocol
- •4\. Patients aged 18 years or older at the time of obtaining informed consent
Exclusion Criteria
- •Patients judged inappropriate for participation in this study by the site\-investigator or sub\-investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A multicenter, prospective, observational study for the association serum pancreatic enzyme level and CT image findings in post-ERCP pancreatitisPost-ERCP pancreatitisJPRN-UMIN000024814Department of Gastroenterology, Kyoto Second Red Cross Hospital5,000
Completed
Not Applicable
A multicenter, prospective, observational study for the incidence and high risk factor of post-ERCP pancreatitisPost-ERCP pancreatitisJPRN-UMIN000024813Department of Gastroenterology, Kyoto Second Red Cross Hospital5,000
Recruiting
Not Applicable
A multicenter, prospective, observational study for the control of delayed chemotherapy-induced nausea and vomiting for upper gastrointestinal cancerJPRN-UMIN000052322agoya University135
Completed
Not Applicable
A prospective, multi-centre observational study in patients admitted to intensive care to estimate daily sodium balanceACTRN12612000046808Shailesh Bihari50
Completed
Phase 4
A Prospective, Multicenter, Observational Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated with Ixazomib plus Lenalidomide and DexamethasoneRelapsed and/or Refractory Multiple MyelomaJPRN-UMIN000031216Takeda Pharmaceutical Company Limited300